Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Patients with locally advanced or clinically node positive urothelial carcinoma treated with
chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.